Type II diabetes is a metabolic disease the increases in incidence and prevalence with age. Type II diabetes (also known as "adult onset diabetes" and "non-insulin dependent diabetes") is a disease of glucose metabolism in which the individual becomes resistant to the glucose produced by the pancreas. As a result, glucose is not properly metabolized and serum glucose levels are increased, resulting in numerous complications vascular, renal, neurological and ophthalmological complications as the patient ages.
This volume of the Markets in Geriatric Medicine Series will look at the mechanisms involved in the pathology of both Type II diabetes, and the specific molecular processes that define this disease. The report will look at the technology and markets available for monitoring glucose levels, by patients, and the assays for hemoglobin A1C, ketones and microalbumin that are used to follow the progress of the disease and its complications.
It will also explore current treatment modalities for Type II diabetes, including oral hypoglycemics and insulin. It will describe new and emerging research and development efforts into the discovery of new therapeutic products that address this disease such as new oral hypoglycemic agents and both oral and inhaled dosage forms of insulin. We will investigate and discuss the latest in progress towards clinical development of biopharmaceuticals and cell-based therapeutics that may be introduced over the next decade for the treatment of Type II diabetes at its most basic level.
The report will look at the demographics of the aging United States population, the expected incidence and prevalence of Type II diabetes, and the United States markets for monitoring products and therapeutics, currently estimated at $4.5 billion and $5.5 billion, respectively, that are expected grow around these populations.
CHAPTER ONE: EXECUTIVE SUMMARY
- Background
- Scope and Methodology
- Size and Growth of Market
- Market Trends and Factors
CHAPTER TWO: INTRODUCTION
- Background
- Population Demographics
- Epidemiology and Pathology of Type II Diabetes
CHAPTER THREE: DIABETES MONITORING
- Background
- Glucose Monitoring
- Hemoglobin A1c
- Ketone Monitoring
- Microalbumin Monitoring
CHAPTER FOUR: TYPE II DIABETES THERAPEUTICS
- Current Approaches to Therapy
- Patient Education
- Exercise, Diet and Weight Control
- Oral Hypoglycemic Agents
- Insulin
- Emerging Therapeutic Approaches
- Prevention
- Oral Hypoglycemic Agents
- Insulin
- Gene Therapy
- Aeta Cell Transplants
CHAPTER FIVE: MARKET ANALYSIS
- Market Size and Growth
- Type II Diabetes Monitoring Markets
- Insulin Therapy Markets
- Oral Hypoglycemic Drugs
- Competitive Outlook
- Type II Diabetes Monitoring Markets
- Insulin Therapy Markets
- Oral Hypoglycemic Drug Markets
- Market Trends
CHAPTER SIX: COMPANY PROFILES
- Overview
- Abbott Laboratories
- Alkermes, Inc
- Amylin Pharmaceuticals
- Aventis Pharma U.S. Division of Aventis
- The Bayer Group (USA) Subsidiary of Bayer AG
- Bristol-Myers Squibb1
- Calyx Therapeutics
- GlaxoSmithKline
- Lexicon Genetics Corporation
- Eli Lilly & Co
- Metabolex, Inc
- MitoKor
- Novo Nordisk
- Pfizer, Inc
- Takeda Pharmaceuticals North America
- Telik, Inc
CHAPTER SEVEN: CONCLUSIONS AND STRATEGIC IMPLICATIONS
- First Conclusion
- Second Conclusion
- Third Conclusion
- Fourth Conclusion
- Fifth Conclusion
- Sixth Conclusion
- Seventh Conclusion
- Eighth Conclusion
- Ninth Conclusion
- Tenth Conclusion
- Eleventh Conclusion
APPENDIX: COMPANY DIRECTORY
医薬品
その他のカテゴリ
FAQ